JP2022543244A - ヒトスクアラミン誘導体、それを含む関連組成物、およびそれを用いた方法 - Google Patents

ヒトスクアラミン誘導体、それを含む関連組成物、およびそれを用いた方法 Download PDF

Info

Publication number
JP2022543244A
JP2022543244A JP2022506659A JP2022506659A JP2022543244A JP 2022543244 A JP2022543244 A JP 2022543244A JP 2022506659 A JP2022506659 A JP 2022506659A JP 2022506659 A JP2022506659 A JP 2022506659A JP 2022543244 A JP2022543244 A JP 2022543244A
Authority
JP
Japan
Prior art keywords
aminosterol
optionally substituted
compound
subject
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506659A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543244A5 (https=
Inventor
デニス バーブット、
マイケル ザスロフ、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enterin Inc
Original Assignee
Enterin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterin Inc filed Critical Enterin Inc
Publication of JP2022543244A publication Critical patent/JP2022543244A/ja
Publication of JP2022543244A5 publication Critical patent/JP2022543244A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022506659A 2019-08-02 2020-07-31 ヒトスクアラミン誘導体、それを含む関連組成物、およびそれを用いた方法 Pending JP2022543244A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962882318P 2019-08-02 2019-08-02
US62/882,318 2019-08-02
US202063036828P 2020-06-09 2020-06-09
US63/036,828 2020-06-09
PCT/US2020/044392 WO2021025974A1 (en) 2019-08-02 2020-07-31 Human squalamine derivatives, related compositions comprising the same, and methods of using the same

Publications (2)

Publication Number Publication Date
JP2022543244A true JP2022543244A (ja) 2022-10-11
JP2022543244A5 JP2022543244A5 (https=) 2023-08-07

Family

ID=74503104

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506659A Pending JP2022543244A (ja) 2019-08-02 2020-07-31 ヒトスクアラミン誘導体、それを含む関連組成物、およびそれを用いた方法

Country Status (5)

Country Link
US (1) US20220372066A1 (https=)
EP (1) EP4007765A4 (https=)
JP (1) JP2022543244A (https=)
CA (1) CA3149480A1 (https=)
WO (1) WO2021025974A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12503485B2 (en) 2019-08-02 2025-12-23 Enterin, Inc. Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same
WO2021216399A1 (en) * 2020-04-20 2021-10-28 Enterin, Inc. Pulmonary aminosterol compositions and methods of using the same to treat microbial infections
WO2022226116A1 (en) * 2021-04-21 2022-10-27 Oxeia Biopharmaceuticals, Inc. Ghrelin treatment of brain dysfunction due to viral infection
WO2023038858A1 (en) * 2021-09-10 2023-03-16 Edifice Health, Inc. Methods and compositions for diagnosing and treating covid-19
CN113975278B (zh) * 2021-10-29 2023-04-07 中国科学院昆明动物研究所 溴隐亭在制备治疗非洲猪瘟的产品中的应用
WO2023146838A1 (en) * 2022-01-25 2023-08-03 Enterin, Inc. Methods for treating or preventing neurodegenerative disease using a combination of aminosterols and an insulin compound
WO2023146842A1 (en) * 2022-01-25 2023-08-03 Enterin, Inc. C25 r and s isomers of aminosterols and methods of making and using the same
CN118085053A (zh) * 2022-11-25 2024-05-28 深圳先进技术研究院 以Inx5基因或以Inx5蛋白作为作用靶点的物质的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040728A2 (en) * 1995-06-07 1996-12-19 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (nhe), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the nhe-inhibitory efficacy of compounds
WO1996040151A1 (en) * 1995-06-07 1996-12-19 Magainin Pharmaceuticals Inc. Use of squalamine for the manufacture of a medicament for inhibiting nhe
WO1998027106A1 (en) * 1996-12-18 1998-06-25 Magainin Pharmaceuticals Inc. Aminosterol ester compounds
WO2009032321A2 (en) * 2007-09-06 2009-03-12 Genaera Corporation A method for treating diabetes
WO2014132052A2 (en) * 2013-02-27 2014-09-04 Swansea University Compound and method for the treatment and diagnosis of neurodegenerative conditions
WO2015036726A1 (en) * 2013-09-10 2015-03-19 Swansea University Deuterated compounds
WO2018050815A1 (fr) * 2016-09-15 2018-03-22 Virbac Dérivés amides de squalamine pour le traitement des infections
WO2018050814A1 (fr) * 2016-09-15 2018-03-22 Virbac Esters des derivés 3-polyaminés des acides biliaires pour le traitement des infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020520A1 (en) * 1993-03-10 1994-09-15 Magainin Pharmaceuticals Inc. Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
MX367255B (es) * 2012-04-20 2019-08-12 Ohr Pharmaceutical Inc Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b).
EP2934543B1 (en) * 2012-12-20 2018-10-31 Mount Desert Island Biological Laboratory Stimulation and enhancement of regeneration of tissues
EP3083656A1 (en) * 2013-12-20 2016-10-26 Prevacus Inc. Synthesis of ent-progesterone and intermediates thereof
US20230125585A1 (en) * 2019-08-02 2023-04-27 Enterin, Inc. Dosing protocols and regimens for aminosterol treatment
US12503485B2 (en) * 2019-08-02 2025-12-23 Enterin, Inc. Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040728A2 (en) * 1995-06-07 1996-12-19 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (nhe), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the nhe-inhibitory efficacy of compounds
WO1996040151A1 (en) * 1995-06-07 1996-12-19 Magainin Pharmaceuticals Inc. Use of squalamine for the manufacture of a medicament for inhibiting nhe
WO1998027106A1 (en) * 1996-12-18 1998-06-25 Magainin Pharmaceuticals Inc. Aminosterol ester compounds
WO2009032321A2 (en) * 2007-09-06 2009-03-12 Genaera Corporation A method for treating diabetes
WO2014132052A2 (en) * 2013-02-27 2014-09-04 Swansea University Compound and method for the treatment and diagnosis of neurodegenerative conditions
WO2015036726A1 (en) * 2013-09-10 2015-03-19 Swansea University Deuterated compounds
WO2018050815A1 (fr) * 2016-09-15 2018-03-22 Virbac Dérivés amides de squalamine pour le traitement des infections
WO2018050814A1 (fr) * 2016-09-15 2018-03-22 Virbac Esters des derivés 3-polyaminés des acides biliaires pour le traitement des infections

Also Published As

Publication number Publication date
CA3149480A1 (en) 2021-02-11
US20220372066A1 (en) 2022-11-24
EP4007765A1 (en) 2022-06-08
EP4007765A4 (en) 2023-08-23
WO2021025974A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
JP2022543244A (ja) ヒトスクアラミン誘導体、それを含む関連組成物、およびそれを用いた方法
US20260098052A1 (en) Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same
US20220152057A1 (en) Methods and compositions for treating various disorders
TWI879741B (zh) 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
US20200262864A1 (en) Deuterated forms of aminosterols and methods of using the same
US20190298740A1 (en) Methods and compositions for treating hallucinations and conditions related to the same
US20240277732A1 (en) Compositions and methods for treating brain-gut disorders
EP4427738A2 (en) Dosing protocols and regimens for aminosterol treatment
US20210260078A1 (en) Low dosage intranasal aminosterol dosage forms and methods of using the same
US20200038420A1 (en) Aminosterol compositions and methods of using the same for treating depression
US20210315907A1 (en) Compositions and methods for treating brain-gut disorders
WO2023146838A1 (en) Methods for treating or preventing neurodegenerative disease using a combination of aminosterols and an insulin compound
AU2020324937B2 (en) Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same
US20230159582A1 (en) Crystalline forms of squalamine
US20240100069A1 (en) Methods and Compositions for Treating Amyotrophic Lateral Sclerosis
US20200038417A1 (en) Methods and compositions for treating cognitive impairment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250408